Rethinking mechanisms of neurotoxicity with BCMA directed therapy
- 27 August 2021
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 166, 103453
- https://doi.org/10.1016/j.critrevonc.2021.103453
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple MyelomaTargeted Oncology, 2017
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T CellsCancer Discovery, 2017
- Photophobia in neurologic disordersTranslational Neurodegeneration, 2017
- Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myelomaBritish Journal of Haematology, 2016
- Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRILMolecular and Cellular Neuroscience, 2014
- Cognitive-motor interactions of the basal ganglia in developmentFrontiers in Systems Neuroscience, 2014
- Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemiaClinical Pharmacology: Advances and Applications, 2013
- Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survivalBlood, 2004
- A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member April, Inhibits Tumor Cell GrowthThe Journal of Experimental Medicine, 2000
- The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamilyInternational Immunology, 1998